Biogen research chief says 'misinformation' is cause for controversy surrounding Alzheimer's drug

Biogen R&D chief says that misinformation is at the heart of the controversy surrounding Aduhelm, his companies newly approved Alzheimer's drug.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news